Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

mogamulizumab 7Specimen Handling 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5Biopsy 5pembrolizumab 4fludarabine 4Magnetic Resonance Spectroscopy 4Brentuximab Vedotin 4hypericin 3fludarabine phosphate 3cemiplimab 3Radiotherapy 3Nivolumab 3sodium-iodide symporter 2X-Rays 2Whole-Body Irradiation 2Tacrolimus 2Phototherapy 2Photons 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Busulfan 2talimogene laherparepvec 1ruxolitinib 1romidepsin 1magrolimab 1duvelisib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × AFM13 × 1 year × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡